{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T21:09:32Z","timestamp":1778101772839,"version":"3.51.4"},"reference-count":79,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T00:00:00Z","timestamp":1660348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>A novel class of oral glucose lowering drugs, sodium-glucose co-transporter type 2 inhibitors (SGLT2is), has shown additional beneficial effects on body weight, serum uric acid levels, blood pressure, and cardiac and renal function. Conflicting data have been published regarding the potential risk of acute kidney injury (AKI) when using SGLT2is. Aim of this manuscript was to review the current literature on this issue. SGLT2is\u00a0induce a mild acute decline in estimated glomerular filtration rate, attributed to the effect of proximal tubular natriuresis on tubuloglomerular feedback through increased macula densa sodium delivery, leading to afferent arteriole vasoconstriction and reduced intraglomerular pressure. This functional effect with a subsequent rise in serum creatinine fulfills the creatinine-based\u00a0criteria for AKI,\u00a0as defined in clinical practice and trial settings. Other proposed potential mechanisms as to\u00a0how SGLT2is\u00a0lead to AKI include osmotic diuresis leading to volume depletion, increased urinary uric acid levels, intratubular oxidative stress, local inflammation and tubular injury. Despite the warning published by the US Food and Drug Administration in 2016 about a potential risk of AKI and the report of some clinical cases of AKI after treatment with SGLT2is, large observational real-life retrospective studies, randomized controlled trials and propensity-matched analyses of data from clinical practice unambiguously demonstrate that SGLT2is are safe for the kidney and do not predispose to AKI. In conclusion, while we can probably stop worrying about AKI risk when using SGLT2is, the question whether these agents should be withheld in the presence of clinical situations at high risk for AKI\u00a0remains unaddressed.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s40620-022-01422-w","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T05:03:11Z","timestamp":1660366991000},"page":"31-43","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Is there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0190-2746","authenticated-orcid":false,"given":"Sidar","family":"Copur","sequence":"first","affiliation":[{"name":"Department of Medicine, Koc University School of Medicine, Istanbul, Turkey 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdullah","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Department of Medicine, Koc University School of Medicine, Istanbul, Turkey 1"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8152-5471","authenticated-orcid":false,"given":"Carlo","family":"Basile","sequence":"additional","affiliation":[{"name":"Associazione Nefrologica Gabriella Sebastio, Martina Franca, Italy 2"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2235-0103","authenticated-orcid":false,"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[{"name":"Division of Nephrology, University of Washington, Seattle, WA, USA 3"},{"name":"Providence Medical Research Center, Providence Health Care, Washington, USA 4"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-0675","authenticated-orcid":false,"given":"Mehmet","family":"Kanbay","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Koc University School of Medicine, Istanbul, Turkey 5"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,8,13]]},"reference":[{"key":"2026012307482101700_CR1","first-page":"49","article-title":"Diabetic kidney disease: world wide difference of prevalence and risk factors","volume":"5","author":"Gheith","year":"2015","journal-title":"J Nephropharmacol"},{"key":"2026012307482101700_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158765","article-title":"Global prevalence of chronic kidney disease\u2014a systematic review and meta-analysis","volume":"11","author":"Hill","year":"2016","journal-title":"PLoS\u00a0One"},{"key":"2026012307482101700_CR3","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2026012307482101700_CR4","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2026012307482101700_CR5"},{"key":"2026012307482101700_CR6","doi-asserted-by":"publisher","first-page":"e002496","DOI":"10.1136\/bmjdrc-2021-002496","article-title":"Renal effectiveness and safety of the sodium-glucose cotransporter-2 inhibitors: a population-based cohort study","volume":"9","author":"Alkabbani","year":"2021","journal-title":"BMJ Open Diabetes Res Care"},{"key":"2026012307482101700_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.781379","article-title":"Comparison of adverse kidney outcomes with empagliflozin and linagliptin use in patients with type 2 diabetic patients in a real-world setting","volume":"12","author":"Lee","year":"2021","journal-title":"Front Pharmacol"},{"key":"2026012307482101700_CR8","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1053\/j.ajkd.2021.09.015","article-title":"SGLT2 inhibitors and the risk of acute kidney injury in older adults with type 2 diabetes","volume":"79","author":"Zhuo","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2026012307482101700_CR9","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1053\/j.ajkd.2020.03.019","article-title":"Acute kidney injury events in patients with type 2 diabetes using SGLT2 inhibitors versus other glucose-lowering drugs: a retrospective cohort study","volume":"76","author":"Rampersad","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026012307482101700_CR10","doi-asserted-by":"publisher","first-page":"E351","DOI":"10.1503\/cmaj.191283","article-title":"Use of sodium-glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study","volume":"192","author":"Iskander","year":"2020","journal-title":"CMAJ"},{"key":"2026012307482101700_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1186","article-title":"Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study","volume":"369","author":"Pasternak","year":"2020","journal-title":"BMJ"},{"key":"2026012307482101700_CR12","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1111\/jdi.13064","article-title":"Protective effect of sodium-glucose cotransporter 2 inhibitors in patients with rapid renal function decline, stage G3 or G4 chronic kidney disease and type 2 diabetes","volume":"10","author":"Miyoshi","year":"2019","journal-title":"J Diabetes Investig"},{"key":"2026012307482101700_CR13","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3389\/fendo.2019.00820","article-title":"Renal and glucose-lowering effects of empagliflozin and dapagliflozin in different chronic kidney disease stages","volume":"10","author":"Lin","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026012307482101700_CR14","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/dom.13532","article-title":"Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis","volume":"21","author":"Cahn","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026012307482101700_CR15","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2337\/dc17-1011","article-title":"Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis","volume":"40","author":"Nadkarni","year":"2017","journal-title":"Diabetes Care"},{"key":"2026012307482101700_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.2337\/dc19-1476","article-title":"Efficacy and safety of dapagliflozin in the elderly: analysis from the DECLARE-TIMI 58 study","volume":"43","author":"Cahn","year":"2020","journal-title":"Diabetes Care"},{"key":"2026012307482101700_CR17","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012307482101700_CR18","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular Outcomes with ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012307482101700_CR19","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of Canagliflozin in patients with baseline eGFR &lt;30 ml\/min per 1.73 m(2): subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026012307482101700_CR20","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012307482101700_CR21","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"2026012307482101700_CR22","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012307482101700_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-022577","article-title":"Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis","volume":"9","author":"Donnan","year":"2019","journal-title":"BMJ Open"},{"key":"2026012307482101700_CR24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002983","article-title":"Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis","volume":"16","author":"Menne","year":"2019","journal-title":"PLoS Med"},{"key":"2026012307482101700_CR25","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1111\/dom.13754","article-title":"Acute kidney injury with sodium-glucose co-transporter-2 inhibitors: a meta-analysis of cardiovascular outcome trials","volume":"21","author":"Gilbert","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"2026012307482101700_CR26","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s40261-020-00925-3","article-title":"Acute renal failure, ketoacidosis, and urogenital tract infections with SGLT2 inhibitors: signal detection using a Japanese spontaneous reporting database","volume":"40","author":"Katsuhara","year":"2020","journal-title":"Clin Drug Investig"},{"key":"2026012307482101700_CR27","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40261-021-01006-9","article-title":"Correlations between SGLT-2 inhibitors and acute renal failure by signal detection using FAERS: stratified analysis for reporting country and concomitant drugs","volume":"41","author":"Katsuhara","year":"2021","journal-title":"Clin Drug Investig"},{"key":"2026012307482101700_CR28","doi-asserted-by":"publisher","first-page":"e40","DOI":"10.2337\/dc16-2200","article-title":"Potential hypoxic renal injury in patients with diabetes on SGLT2 inhibitors: caution regarding concomitant use of NSAIDs and iodinated contrast media","volume":"40","author":"Heyman","year":"2017","journal-title":"Diabetes Care"},{"key":"2026012307482101700_CR29","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"2026012307482101700_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","article-title":"Renal, metabolic and cardiovascular considerations of SGLT2 inhibition","volume":"13","author":"DeFronzo","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2026012307482101700_CR31","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1152\/physrev.00055.2009","article-title":"Biology of human sodium glucose transporters","volume":"91","author":"Wright","year":"2011","journal-title":"Physiol Rev"},{"key":"2026012307482101700_CR32","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1681\/ASN.2016030278","article-title":"Canagliflozin slows progression of renal function decline independently of glycemic effects","volume":"28","author":"Heerspink","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026012307482101700_CR33","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"2026012307482101700_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/nrneph.2016.159","article-title":"Acute kidney injury from SGLT2 inhibitors: potential mechanisms","volume":"12","author":"Hahn","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"2026012307482101700_CR35","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.jare.2016.09.006","article-title":"Serum uric acid and acute kidney injury: a mini review","volume":"8","author":"Hahn","year":"2017","journal-title":"J Adv Res"},{"key":"2026012307482101700_CR36","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1007\/s00125-015-3650-4","article-title":"Fructose and uric acid in diabetic nephropathy","volume":"58","author":"Bjornstad","year":"2015","journal-title":"Diabetologia"},{"key":"2026012307482101700_CR37","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","article-title":"Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia","volume":"41","author":"Szalat","year":"2018","journal-title":"Drug Saf"},{"key":"2026012307482101700_CR38","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"2026012307482101700_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1097\/00041552-199807000-00016","article-title":"Role of macula densa NOS in tubuloglomerular feedback","volume":"7","author":"Wilcox","year":"1998","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026012307482101700_CR40","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00125-016-4157-3","article-title":"Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition","volume":"60","author":"Vallon","year":"2017","journal-title":"Diabetologia"},{"key":"2026012307482101700_CR41","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1681\/ASN.V10122569","article-title":"Glomerular hyperfiltration in experimental diabetes mellitus: potential role of tubular reabsorption","volume":"10","author":"Vallon","year":"1999","journal-title":"J Am Soc Nephrol"},{"key":"2026012307482101700_CR42","doi-asserted-by":"publisher","first-page":"F1269","DOI":"10.1152\/ajprenal.00543.2015","article-title":"Predicted consequences of diabetes and SGLT inhibition on transport and oxygen consumption along a rat nephron","volume":"310","author":"Layton","year":"2016","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012307482101700_CR43","doi-asserted-by":"publisher","first-page":"F227","DOI":"10.1152\/ajprenal.00689.2014","article-title":"Acute SGLT inhibition normalizes O2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats","volume":"309","author":"O'Neill","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012307482101700_CR44","doi-asserted-by":"publisher","first-page":"F156","DOI":"10.1152\/ajprenal.00409.2012","article-title":"Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus","volume":"304","author":"Vallon","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012307482101700_CR45","doi-asserted-by":"publisher","first-page":"F969","DOI":"10.1152\/ajprenal.00551.2017","article-title":"SGLT2 inhibition in a kidney with reduced nephron number: modeling and analysis of solute transport and metabolism","volume":"314","author":"Layton","year":"2018","journal-title":"Am J Physiol Renal Physiol"},{"issue":"15","key":"2026012307482101700_CR46","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.98720","article-title":"SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy","volume":"3","author":"Cassis","year":"2018","journal-title":"JCI Insight"},{"key":"2026012307482101700_CR47","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/cphy.c100049","article-title":"Pathophysiology of the diabetic kidney","volume":"1","author":"Vallon","year":"2011","journal-title":"Compr Physiol"},{"key":"2026012307482101700_CR48","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/MNH.0000000000000343","article-title":"Do effects of sodium-glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease?","volume":"26","author":"Rajasekeran","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2026012307482101700_CR49","doi-asserted-by":"publisher","first-page":"F194","DOI":"10.1152\/ajprenal.00520.2013","article-title":"SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice","volume":"306","author":"Vallon","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012307482101700_CR50","doi-asserted-by":"publisher","first-page":"F317","DOI":"10.1152\/ajprenal.00145.2014","article-title":"The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob\/ob type 2 diabetic mice with and without hypertension","volume":"307","author":"Gembardt","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"2026012307482101700_CR51","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0100777","article-title":"Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db\/db mice","volume":"9","author":"Terami","year":"2014","journal-title":"PLoS\u00a0One"},{"key":"2026012307482101700_CR52","doi-asserted-by":"publisher","first-page":"5335","DOI":"10.1074\/jbc.M117.779520","article-title":"SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein inhibition decreases renal lipid accumulation, inflammation, and the development of nephropathy in diabetic mice","volume":"292","author":"Wang","year":"2017","journal-title":"J Biol Chem"},{"key":"2026012307482101700_CR53","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054442","article-title":"Effects of SGLT2 inhibition in human kidney proximal tubular cells\u2013renoprotection in diabetic nephropathy?","volume":"8","author":"Panchapakesan","year":"2013","journal-title":"PLoS\u00a0One"},{"key":"2026012307482101700_CR54","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1053\/j.ajkd.2020.05.014","article-title":"We can finally stop worrying about SGLT2 inhibitors and acute kidney injury","volume":"76","author":"Sridhar","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026012307482101700_CR55","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012307482101700_CR56","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1161\/CIRCULATIONAHA.120.051685","article-title":"Cardiac and kidney benefits of empagliflozin in heart failure across the spectrum of kidney function: insights from EMPEROR-reduced","volume":"143","author":"Zannad","year":"2021","journal-title":"Circulation"},{"key":"2026012307482101700_CR57","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1161\/CIRCULATIONAHA.120.050391","article-title":"Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF","volume":"143","author":"Jhund","year":"2021","journal-title":"Circulation"},{"key":"2026012307482101700_CR58","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1681\/ASN.2015030309","article-title":"Progression after AKI: understanding maladaptive repair processes to predict and identify therapeutic treatments","volume":"27","author":"Basile","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2026012307482101700_CR59","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"2026012307482101700_CR60","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1111\/ajt.15369","article-title":"Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity","volume":"19","author":"Cantarelli","year":"2019","journal-title":"Am J Transplant"},{"key":"2026012307482101700_CR61","doi-asserted-by":"publisher","first-page":"20190562","DOI":"10.1259\/bjr.20190562","article-title":"Non-invasive assessment of early stage diabetic nephropathy by DTI and BOLD MRI","volume":"93","author":"Feng","year":"2020","journal-title":"Br J Radiol"},{"key":"2026012307482101700_CR62","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"key":"2026012307482101700_CR63","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1053\/j.ajkd.2020.04.016","article-title":"Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics","volume":"77","author":"Packer","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2026012307482101700_CR64","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1038\/s41419-020-2544-7","article-title":"Sodium-glucose cotransporter 2 inhibition suppresses HIF-1\u03b1-mediated metabolic switch from lipid oxidation to glycolysis in kidney tubule cells of diabetic mice","volume":"11","author":"Cai","year":"2020","journal-title":"Cell Death Dis"},{"key":"2026012307482101700_CR65","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11886-019-1165-1","article-title":"Effect of SGLT2 inhibitors on the sympathetic nervous system and blood pressure","volume":"21","author":"Scheen","year":"2019","journal-title":"Curr Cardiol Rep"},{"key":"2026012307482101700_CR66","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: effects in acute and chronic kidney disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Curr Diab Rep"},{"key":"2026012307482101700_CR67","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1111\/dom.13301","article-title":"Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers","volume":"20","author":"Dekkers","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2026012307482101700_CR68","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1093\/ckj\/sfy122","article-title":"Effect of sodium-glucose cotransporter 2 inhibitor on proximal tubular function and injury in patients with type 2 diabetes: a randomized controlled trial","volume":"12","author":"Satirapoj","year":"2019","journal-title":"Clin Kidney J"},{"key":"2026012307482101700_CR69","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1093\/ckj\/sfaa033","article-title":"Acute interstitial nephritis due to sodium-glucose co-transporter 2 inhibitor empagliflozin","volume":"14","author":"Ryan","year":"2021","journal-title":"Clin Kidney J"},{"key":"2026012307482101700_CR70","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1093\/ckj\/sfy090","article-title":"The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study","volume":"11","author":"Herrington","year":"2018","journal-title":"Clin Kidney J"},{"key":"2026012307482101700_CR71","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"2026012307482101700_CR72","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-11-43","article-title":"Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial","volume":"11","author":"Bailey","year":"2013","journal-title":"BMC Med"},{"key":"2026012307482101700_CR73","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1111\/j.1463-1326.2012.01659.x","article-title":"Dapagliflozin monotherapy in drug-na\u00efve patients with diabetes: a randomized-controlled trial of low-dose range","volume":"14","author":"Bailey","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"2026012307482101700_CR74","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.2337\/dc14-0315","article-title":"Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension","volume":"38","author":"Cefalu","year":"2015","journal-title":"Diabetes Care"},{"key":"2026012307482101700_CR75","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","article-title":"Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control","volume":"85","author":"Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"2026012307482101700_CR76","doi-asserted-by":"publisher","first-page":"355","DOI":"10.2337\/dc13-2762","article-title":"Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study","volume":"38","author":"Leiter","year":"2015","journal-title":"Diabetes Care"},{"key":"2026012307482101700_CR77"},{"key":"2026012307482101700_CR78","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2337\/dc16-1347","article-title":"Empagliflozin as add-on therapy in patients with type 2 diabetes inadequately controlled with linagliptin and metformin: a 24-week randomized, double-blind, parallel-group trial","volume":"40","author":"S\u00f8fteland","year":"2017","journal-title":"Diabetes Care"},{"key":"2026012307482101700_CR79","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1042\/CS20171298","article-title":"SGLT2 inhibition and kidney protection","volume":"132","author":"Nespoux","year":"2018","journal-title":"Clin Sci (Lond)"}],"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01422-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40620-022-01422-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/36\/1\/31\/66555998\/joneph_36_1_1422.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40620-022-01422-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/academic.oup.com\/joneph\/article-pdf\/36\/1\/31\/66555998\/joneph_36_1_1422.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T12:48:30Z","timestamp":1769172510000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/article\/36\/1\/31\/8383884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,8,13]]},"published-print":{"date-parts":[[2023,1,1]]}},"URL":"https:\/\/doi.org\/10.1007\/s40620-022-01422-w","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,1,1]]},"published":{"date-parts":[[2022,8,13]]},"assertion":[{"value":"1 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure of potential conflicts of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"No verbal and written informed consent was necessary for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}